Navigation Links
NIH Recovery Act awards enable crucial health research technologies
Date:10/21/2010

Leading-edge, shared technologies are an important component of advancing research to improve health. Specialized instruments such as high-powered electron microscopes, high-resolution mass spectrometers and supercomputers that rapidly process vast amounts of data can enable breakthrough discoveries in preventions, treatments and cures for diseases.

Thanks to the Recovery Act, more health scientists now will have access to these state-of-the-art devices, the National Institutes of Health announced today. Through its National Center for Research Resources (NCRR), NIH has awarded $300 million in shared instrumentation grants.

In total, NCRR awarded more than 450 Recovery Act instrumentation grants to groups of NIH-funded scientists in 42 states and the District of Columbia. The grants, which range from $100,000 to $8 million, enable the purchase of technology that is vital to promising research projects.

"These Recovery Act awards make world class resources available to scientists nationwide," said NIH Director Francis S. Collins, M.D., Ph.D. "More researchers now will have access to the latest technologies that accelerate the pace of biomedical research, ultimately leading to new advances and treatments for diseases."

Following are three types of technologies and instruments funded by these grants, all of which have the potential to enhance a wide variety of biomedical research in many disease areas.

  • Researchers at the University of Minnesota in Minneapolis will use a $7.8 million grant to purchase components of a 10.5 Tesla whole-body magnetic resonance imaging system. This instrument will be the most powerful of its kind in the world, providing scientists with unprecedented views inside the human body. In the past two decades, researchers have made great strides in developing instruments with increasingly powerful magnetic fields that can zoom in on finer structures. The 10.5 Tesla magnet will push the technology even further and allow them to see more details of the human brain, as well as the human torso and extremities, thereby improving disease detection and treatment monitoring.

  • Using nearly $8 million, investigators at the University of Maryland, Baltimore have purchased a powerful 950 megahertz nuclear magnetic resonance spectrometer, to study human tissues and cells in atomic detail. Researchers from across the mid-Atlantic region will use this imaging device one of just two in the country to identify new ways to treat cancer, HIV/AIDS and heart disease, and to design more effective drugs. These spectrometers apply strong magnetic fields to biological samples to extract information about the identity and locations of atoms within proteins, fats and other molecules. By analyzing cells and tissues in such detail, researchers can learn about disease processes and possible treatments.

  • To examine cell division in detail, researchers at the University of Washington in Seattle will use a nearly $215,000 award to develop a multicolor total internal reflection fluorescence microscope. This instrument overcomes a major obstacle of conventional fluorescence microscopy that leads to blurry images when fluorescent target molecules inside a cell are too close to one another. Using this microscope, researchers at the University of Washington plan to obtain detailed views of the cellular apparatus components responsible for pulling apart chromosomes as cells divide. The insights gained promise to revolutionize the design of cancer drugs that target these components.

"Innovative research requires access to the latest technologies," said NCRR Director Barbara Alving, M.D. "These high-performance tools will ensure that NIH-funded investigators remain at the forefront of modern biomedical research."

NCRR's instrumentation grants fall under two categories. The Shared Instrumentation Grant (SIG) program provides funding for NIH-supported investigators to obtain equipment in the $100,000 to $600,000 price range. Examples of instrumentation supported by SIG funding include nuclear magnetic resonance systems, cell sorters, and protein and DNA sequencers. The High-End Instrumentation (HEI) grant program supports the purchase of sophisticated research equipment costing more than $750,000 with a ceiling of $2 million. For the Recovery Act awards, the floor for the HEI program was adjusted to $600,000 and the ceiling was raised to $8 million to accommodate a broader range of technologies. Instruments in this price range include high-resolution mass spectrometers, electron microscopes and supercomputers.

SIG and HEI grants are highly cost-effective because the programs require that each instrument be shared by at least three researchers. Approximately eight to 10 investigators will share each of the instruments funded through this Recovery Act program, enabling a reach of more than 3,500 scientists nationwide.


'/>"/>

Contact: Bobbi Gardner
bobbi.gardner@nih.gov
310-443-9919
NIH/National Center for Research Resources
Source:Eurekalert

Related medicine news :

1. Recovery Act's One Year Anniversary -- 2009 Was Just the Opening Act
2. Federal Recovery Funds Allow Eries Shriners Hospital to Reduce Energy Costs, Invest Savings in Patient Care
3. U.S. Senate Urgently Needs to Extend Medicaid Match in Economic Recovery Legislation
4. Alliance, Inc. Receives Centers of Excellence in Recovery Grant
5. De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V
6. San Francisco Plastic Surgeon Releases Plastic Surgery Patient Recovery Blog
7. Passages to Recovery Outdoor Addiction Treatment Program Achieves Joint Commission Accreditation
8. Economic Recovery and New Healthcare Legislation: The Stars Are Aligned for Increased Adoption of HR Management Systems (HRMS)
9. New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates' Number One Concern: Recovery Time
10. Arizona Surgeon Performs Hip Replacement Surgery with Fast Recovery, Less Pain
11. Addiction and Recovery: Life Force Dallas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... An in-depth computational analysis of genetic variants implicated in both ... genes that may explain why susceptibility to one of the disorders could place individuals ... today in the journal npj Schizophrenia. , “There is a wealth of genomic ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT ... top priority because it’s not if you will be attacked, but when.” However, he ... comes to digital health care. , Improvements in auditing and monitoring have taken security ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal ... Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, ... his attempts to overcome them. , Schanssema, initially unsure of the career path he ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
(Date:2/24/2017)... ... ... The Radiology Business Management Association will select the 2017 Quest ... Better Radiology Marketing Programs conference, held this year from March 5 to 7 ... given out in five categories. They are:, ,     Patient Marketing, a ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... -- LG Innotek hat heute die weltweit erste 70 mw ... 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C LED ... 280 nm und eignet sich damit für Sterilisationsaufgaben. Es verhindert ... Das Produkt von LG Innotek erzeugt UV-Strahlung im Bereich ... ...
(Date:2/23/2017)... and Markets has announced the addition of the "Menopause Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Menopause ... market? What are the unit prices and annual treatment ...
(Date:2/23/2017)... REDWOOD CITY, Calif. , Feb. 23, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that it will release ... close on Thursday, March 2nd, 2017. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
Breaking Medicine Technology: